The use of Intravenous immunoglobulins (IVIg) has increased due to its therapeutic usefulness in a great number of diseases. Despite this, IVIg label indications remain limited, so it is interesting to study their use off-label.

**Backgrounds**

The use of IVIG in indications unauthorized is frequent (20%), mainly in the field of neurology, which justifies the development of a protocol for the use of IVIG in this field for those indications with more scientific evidence and more common use: demyelinating neuropathies, myasthenia gravis and myopathies.

**Aim and objectives**

To describe the use of IVIG in our hospital for three months and analyze if it has been used for labeled indications.

**Material and methods**

Retrospective study (October-December 2018). Descriptive analysis of the use of immunoglobulins per patient and clinical indication. Information collected from the hospital's information systems and the computer records of the Farmatools® software.

**Results**

The dosage used when IVIg was used as a replacement therapy

200-400 mg / kg every 3-5 weeks

The dosage used when IVIg was used for the rest of indications

1-2 g / kg in 2-5 days

**Conclusion**

The use of IVIG in indications unauthorized is frequent (20%), mainly in the field of neurology, which justifies the development of a protocol for the use of IVIG in this field for those indications with more scientific evidence and more common use: demyelinating neuropathies, myasthenia gravis and myopathies.